Clinico-Epidemiological Profile, Prognostic Factors and Treatment Outcome of Refractory Hodgkin Lymphoma

• Published in: Indian journal of hematology & blood transfusion Vol. 38; no. 2; pp. 274 - 281
• Main Authors: Zenzri, Yosr, Mokrani, Amina, Letaief, Feryel, Ayadi, Mouna, Mezlini, Amel
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.04.2022; Springer Nature B.V
• Subjects: Blood Transfusion Medicine; Chemotherapy; Hematology; Human Genetics; Lymphoma; Medical prognosis; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Stem cell transplantation; Stem cells; Ann Arbor Michigan; United States > US; Autologous stem cell transplant; Chemotherapy; Prognosis; Survival; Hodgkin lymphoma
• ISSN: 0971-4502; 0974-0449; 0974-0449; 0971-4502
• DOI: 10.1007/s12288-021-01463-4

Approximately 5–10% of patients with Hodgkin lymphoma are refractory to initial treatment. The aim of our study was to assess the clinico-epidemiological profile, prognostic factors and treatment outcome. A retrospective study was conducted over a period of 12 years between June 2006 and January 2018 at the oncology department of Salah Azaïz Institute. Thirty-one patients were included. The median age was 27 years with a female predominance (sex ratio = 0.93).The majority had an advanced stage (61%). IGEV regimen was the most commonly used salvage chemotherapy (n = 14). Age above 30 years was predictive of treatment failure after salvage therapy ( p  = 0.003). IGEV regimen showed better results than ICE protocol in terms of response to salvage therapy ( p  = 0.048). Seven patients had salvage radiotherapy. Four patients had autologous stem cell transplant. Progressive disease (n = 12) was the main cause of non-eligibility of autologous stem cell tansplant. Overall survival and progression free survival at 3 years were 50% and 5% respectively. The prognostic factors influencing the overall survival were age above 30 years ( p  = 0.001), advanced Ann Arbor stage before progression ( p  = 0.02), advanced Ann Arbor stage of refractory Hodgkin lymphoma ( p  = 0.001), histological subtype ( p  = 0.001), CD20 expression ( p  = 0.027) and non-response to salvage therapy ( p  = 0.004). The prognostic factor influencing progression free survival was the non-response to salvage therapy ( p  = 0.045). The prognosis of refractory Hodgkin lymphoma remains poor. The current standard secondary treatment consists of combination therapy, usually followed by autologous stem cell transplantat. Innovative therapies are needed to improve the prognosis of refractory Hodgkin lymphoma.